Intermittent Access to GLP-1 Medications Still Leads to Significant Weight Loss

Recent research presented at ENDO 2025 by a prominent weight-loss company highlights that patients struggling with consistent access to GLP-1 receptor agonists, such as semaglutide and tirzepatide, can still achieve meaningful weight loss outcomes. The study analyzed data from 6,392 individuals enrolled in a comprehensive metabolic health program, which integrated medication use with intensive lifestyle interventions focusing on four key pillars: nutrition, exercise, sleep, and emotional health, all supported by personalized coaching.

Participants had at least one month of GLP-1 treatment during the study period, though many experienced disruptions—72.5% faced at least one gap, and 11.1% encountered multiple interruptions. Despite these challenges, those who experienced treatment disruptions still lost an average of 13.7% of their body weight over 12 months and 14.9% over 24 months. In comparison, patients with uninterrupted medication access achieved a higher weight loss of 17% at one year and 20.1% at two years.

Notably, even individuals who received only 1 to 4 medication fills within the first year demonstrated significant weight reductions, exceeding 10%. This underscores the importance of lifestyle modifications and coaching support, which can enhance outcomes even when medication adherence is inconsistent.

Kaelen L. Medeiros, M.S., from Calibrate, emphasized that unpredictable medication availability and insurance hurdles should not deter efforts, as patients can still attain substantial progress through combined lifestyle and treatment strategies. While the most effective approach remains a consistent medication regimen paired with lifestyle support, these findings provide hope for individuals facing access issues.

The study reinforces the critical role of behavioral interventions in weight management and highlights that significant health improvements are achievable despite medication access challenges. For more detailed insights, visit Medical Xpress.